Menu
Close
Global
×

Company News

Company News
Company News
2025-06-25
Immuneonco's IMM0306 Phase Ib Clinical Trial for Systemic Lupus Erythematosus (SLE) Achieves Positive Results with Remarkable Efficacy and Excellent Safety
IMM0306 has demonstrated a strong efficacy signal in the preliminary data for SLE, with efficient and sustained B-cell depletion and immune reconstitution. It has shown rapid and dose-dependent improv
View more
2025-05-22
ImmuneOnco Announced the Phase 2 Trial in First-line NSCLC of IMM2510/AXN-2510, in Combination with Chemotherapy in China is on Track to Complete Enrollment in Q3 2025; Initial Results Anticipated in 2H 2025
ImmuneOnco Announce Clinical Update for the IMM2510/AXN-2510
View more
2025-05-15
The National Medical Products Administration (NMPA) Approved ImmuneOnco’s Clinical Trial Application for Tazlestobart (IMM27M) Combined with Osimertinib in Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Squamous Non-Sma
On May 15, 2025, ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (referred to as “ImmuneOnco,” Hong Kong Stock Exchange stock code: 01541.HK) announced that the Phase Ib/II clinical trial application fo
View more
2025-05-07
Further Payment Received Under the License and Collaboration Agreement with Axion Bio for IMM2510 (Palverafusp α) and IMM27M (Tazlestobart)
This announcement is made by ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (the “Company,” together with its subsidiaries, the “Group”) on a voluntary basis to inform shareholders and potential inve
View more
2025-05-06
ImmuneOnco appoints Dr. Weihai He as Chief Commercial Officer (CBO)
ImmuneOnco is pleased to announce that Dr. Weihai He (“Dr. He”) was appointed as a Chief Business Officer of the Group with effect from May 5, 2025. Dr. He is based in the United States and reports directly to Dr. Tian Wenzhi, the founder, Chairman of the Board, Chief Executive Officer and Chief Scientific Officer of the Company.
View more
2025-04-03
The National Medical Products Administration of the People’s Republic of China (the “NMPA”) Has Accepted the Group’s Application for a Clinical Trial of IMC-003/IMM72 for the Treatment of Pulmonary Arterial Hypertension (PAH)
The National Medical Products Administration of the People’s Republic of China (the “NMPA”) Has Accepted the Group’s Application for a Clinical Trial of IMC-003/IMM72 for the Treatment of Pulmonary Arterial Hypertension (PAH)
View more
总计 70 12345678...1112